Achieve Life Sciences ACHV Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $5.84M-33.3% | $8.76M+0.7% | $8.7M+13.0% | $7.7M+22.9% | $6.27M+17.7% | ||
| $101K+1.0% | $100K+1.0% | $99K-3.9% | $103K+1.0% | $102K+2.0% | ||
| $223K-2.2% | $228K-0.4% | $229K-1.3% | $232K-0.9% | $234K+2.2% | ||
| —— | —— | —— | —— | —— | ||
| $52.45M-4.4% | $54.88M+4.9% | $52.34M+4.4% | $50.11M+9.0% | $45.98M+17.7% | ||
| $908K+10.9% | $819K+7.1% | $765K-18.5% | $939K-39.5% | $1.55M-28.8% | ||
| $1.47M-1.7% | $1.5M-3.5% | $1.55M-7.1% | $1.67M-27.7% | $2.31M-2.0% | ||
| $460K+98.3% | $232K+3,414% | -$7K+97.7% | -$304K-69.8% | -$179K+76.4% | ||
| —— | —— | —— | —— | —— | ||
| -$51.99M+4.9% | -$54.65M-4.4% | -$52.35M-3.8% | -$50.42M-9.2% | -$46.16M-15.9% | ||
| -$1.10+14.1% | -$1.28+7.2% | -$1.38+5.5% | -$1.46-9.0% | -$1.34-8.9% | ||
| -$1.10+14.1% | -$1.28+7.2% | -$1.38+5.5% | -$1.46-9.0% | -$1.34-8.9% | ||
| 182.7M+11.4% | 164M+7.6% | 152.5M+12.3% | 135.8M+0.3% | 135.4M+7.7% | ||
| 182.7M+11.4% | 164M+7.6% | 152.5M+12.3% | 135.8M+0.3% | 135.4M+7.7% | ||
| $5.84M-33.3% | $8.76M+0.7% | $8.7M+13.0% | $7.7M+22.9% | $6.27M+17.7% | ||
| $50K-3.8% | $52K-5.5% | $55K— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $32K-92.2% | $408K-45.2% | $744K+6.3% | $700K+6.1% | $660K+6.3% | ||
| —— | —— | —— | —— | —— | ||
| -$51.99M+4.9% | -$54.67M-4.3% | -$52.41M-4.0% | -$50.41M-9.2% | -$46.16M-16.0% | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | -$0.01+9.1% | -$0.01+8.3% | -$0.01+7.7% | -$0.01+7.1% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| —— | -$54.19M-7.3% | -$50.53M-7.8% | -$46.86M-8.5% | -$43.2M-9.3% | ||
| —— | -$456K-9.7% | -$415.75K-10.7% | -$375.5K-12.0% | -$335.25K-13.6% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $10.86M+5.7% | $10.28M+6.0% | $9.69M+6.4% | $9.11M+6.8% | ||
| —— | -$11.48M-7.3% | -$10.7M-7.8% | -$9.92M-8.5% | -$9.14M-9.3% | ||
| —— | $265K-2.6% | $272K-2.5% | $279K-2.4% | $286K-2.4% | ||
| —— | $1.08M+12.2% | $960.25K+13.8% | $843.5K+16.1% | $726.75K+19.1% | ||
| —— | $17K+871% | $1.75K+113% | -$13.5K+53.0% | -$28.75K+34.7% | ||
| —— | $839K-6.8% | $900.25K-6.4% | $961.5K-6.0% | $1.02M-5.7% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | —— | —— | —— | $99K-86.2% | ||
| —— | —— | —— | —— | —— | ||
| $0— | $0— | $0— | $0— | $0— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | $7.27M+250% | -$4.83M+77.6% | ||
| -$45.31M+8.4% | -$49.47M-21.6% | -$40.68M-2.4% | -$39.72M-11.7% | -$35.57M-19.5% | ||
| —— | 10.0% | 10.0% | 10.0% | 10.0% | ||
| $101K+1.0% | $100K+1.0% | $99K-3.9% | $103K+1.0% | $102K+2.0% | ||
| $57K+3.6% | $55K+5.8% | $52K-3.7% | $54K-3.6% | $56K-5.1% | ||
| -$5K+77.3% | -$22K— | —— | —— | —— | ||
| -$5K+77.3% | -$22K— | —— | —— | —— | ||
| —— | —— | -$48K+5.9% | -$51K-950% | $6K+120% | ||
| —— | $1K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $4M— | —— | —— | —— | ||
| —— | $4K— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $5M— | —— | —— | —— | ||
| $5.84M-33.3% | $8.76M+0.7% | $8.7M+13.0% | $7.7M+22.9% | $6.27M+17.7% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | $8.6M0.0% | $8.6M0.0% | $8.6M0.0% | $8.6M0.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Achieve Life Sciences profitable?
- Achieve Life Sciences is not currently profitable: it reported a net loss of $52.0M over the trailing twelve months.
- What is Achieve Life Sciences's earnings per share?
- Achieve Life Sciences's diluted EPS over the trailing twelve months is $-1.10.
- Where does Achieve Life Sciences's income statement data come from?
- Every line is extracted from Achieve Life Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.